These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 8101360)

  • 1. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
    Chen JF; Aloyo VJ; Weiss B
    Neuroscience; 1993 Jun; 54(3):669-80. PubMed ID: 8101360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of release of acetylcholine in the striatum in mice following continuous exposure to selective D1 and D2 dopaminergic agonists.
    Wang HY; Zhou LW; Friedman E; Weiss B
    Neuropharmacology; 1993 Jan; 32(1):85-91. PubMed ID: 8094235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible blockade of D2 dopamine receptors by fluphenazine-N-mustard increases D2 dopamine receptor mRNA and proenkephalin mRNA and decreases D1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum.
    Chen JF; Aloyo VJ; Qin ZH; Weiss B
    Neurochem Int; 1994 Oct; 25(4):355-66. PubMed ID: 7820070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE; Wooten GF
    Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM; Marin C; Susel Z; Chase TN
    Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated stimulation of D1 dopamine receptors causes time-dependent alterations in the sensitivity of both D1 and D2 dopamine receptors within the rat striatum.
    Hu XT; Brooderson RJ; White FJ
    Neuroscience; 1992 Sep; 50(1):137-47. PubMed ID: 1357592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
    Engber TM; Boldry RC; Kuo S; Chase TN
    Brain Res; 1992 May; 581(2):261-8. PubMed ID: 1356580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.
    Zhou LW; Zhang SP; Qin ZH; Weiss B
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1015-23. PubMed ID: 8113958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation.
    Marin C; Chase TN
    Eur J Pharmacol; 1993 Feb; 231(2):191-6. PubMed ID: 8095897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates.
    Zhang M; Creese I
    Neurosci Lett; 1993 Oct; 161(2):223-6. PubMed ID: 7903803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
    Subramaniam S; Lucki I; McGonigle P
    Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine decreases striatal enkephalin turnover and proenkephalin messenger RNA abundance via D2 receptor activation in primary striatal cell cultures.
    Kowalski C; Giraud P
    Neuroscience; 1993 Apr; 53(3):665-72. PubMed ID: 8487949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole.
    Zhou LW; Qin ZH; Weiss B
    Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha 1 (but not alpha 2)-adrenoceptor agonists in combination with the dopamine D2 agonist quinpirole produce locomotor stimulation in dopamine-depleted mice.
    Eshel G; Ross SB; Kelder D; Edis LE; Jackson DM
    Pharmacol Toxicol; 1990 Aug; 67(2):123-31. PubMed ID: 1979437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum.
    Delfs JM; Kelley AE
    Neuroscience; 1990; 39(1):59-67. PubMed ID: 1982467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
    LaHoste GJ; Yu J; Marshall JF
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
    Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
    Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuously infusing quinpirole decreases Ca2+/calmodulin-dependent phosphorylation in mouse striatum.
    Zhang SP; Zhou LW; Natsukari N; Weiss B
    Neurochem Int; 1993 Oct; 23(4):361-72. PubMed ID: 8220178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.